#USA #New Orleans #Nanoscope #MOGENRY #AAO2026

Nanoscope Therapeutics at Eyecelerator 2026 and AAO Annual Meeting 2026

Nanoscope Therapeutics, Inc., a pioneering biotechnology firm, is slated to take part in two significant ophthalmic events: Eyecelerator 2026 and the American Academy of Ophthalmology (AAO) Annual Meeting set from October 8 to 13 in New Orleans, Louisiana. This participation is poised to accelerate the company’s vision-restoring initiatives and present its advancements in optogenetic therapies.

Key Details of the Participation

During the Eyecelerator event, the Chief Medical Officer, Dr. Sam Barone, will be a panelist on the ‘Emerging Innovations in Retinal Therapies’ panel. Attendees can look forward to insights into new therapeutic approaches aimed at combatting retinal degeneration. Furthermore, the company will deliver a critical presentation detailing the latest data regarding its lead product, MOGENRY (sonpiretigene isteparvovec; MCO-010), as part of the ‘Retina Drug Delivery - New Targets Showcase’.

Eyecelerator Schedule

• - Panel on Innovations

Panelist: Sam Barone, MD, Chief Medical Officer
Date & Time: Thursday, October 8, 2026, from 10:45 to 11:30 AM CT
Location: La Nouvelle Ballroom C

• - Company Presentation

Presenter: Paul Hallen, Chief Operating Officer
Date & Time: Thursday, October 8, 2026, from 1:00 to 1:05 PM CT
Location: Rooms 252–254

Insights at AAO 2026

At the AAO Annual Meeting, Nanoscope will present four-year data from the RESTORE Phase 2b/3 trial concerning MCO-010’s efficacy in treating retinitis pigmentosa. This session is designed to inform the ophthalmology community about the drug's potential in providing durable vision improvement:

• - Session Title: Lasting Vision Improvement in Retinitis Pigmentosa
• - Presenter: Kenneth C. Fan, MD
• - Date & Time: Sunday, October 11, 2026, from 11:42 to 11:49 AM CT
• - Location: Rooms 255–257

Additionally, Dr. David S. Boyer will display a scientific poster regarding improvements in vision for dry age-related macular degeneration utilizing sonpiretigene isteparvovec therapy. The poster is expected to draw interest due to its promising outcomes from the unique phase of the clinical trial.

The Promise of MOGENRY

MOGENRY stands out as an investigational one-time optogenetic therapy that uses Nanoscope’s proprietary technology. The unique aspect of MOGENRY is its ability to activate surviving cells in the retina, allowing them to respond to light and potentially restore vision after the loss of photoreceptors, without the need for genetic tests or invasive surgery.

As Nanoscope aims for a global rollout, the therapy is currently undergoing review by the FDA for retinitis pigmentosa and the PMDA for approval in Japan.

Future Prospects

Overall, Nanoscope's scheduled presentations at both Eyecelerator and AAO are critical for showcasing the incremental advancements in retinal therapies. Beyond MOGENRY, Nanoscope has shown success in multiple clinical trials, reassuring stakeholders of the company’s commitment toward revolutionizing retinal treatment.

Nanoscope Therapeutics will maintain a presence at Booth 2564 throughout the duration of the AAO 2026 conference, providing opportunities for interaction with retina specialists and investors. The leadership team looks forward to discussing collaboration opportunities and the future of retinal care with engaged attendees.